Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)
- 15 April 2014
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 42 (7), 1163-1173
- https://doi.org/10.1124/dmd.114.057000
Abstract
Metabolism by cytochrome P4503A (CYP3A) is the most prevalent clearance pathway for drugs. Designation of metabolism by CYP3A commonly refers to the potential contribution by one or both of two enzymes, CYP3A4 and CYP3A5. The metabolic turnover of 32 drugs known to be largely metabolized by CYP3A was examined in human liver microsomes (HLMs) from CYP3A5 expressers (*1/*1 genotype) and nonexpressers (*3/*3 genotype) in the presence and absence of ketoconazole and CYP3cide (a selective CYP3A4 inactivator) to calculate the contribution of CYP3A5 to metabolism. Drugs with the highest contribution of CYP3A5 included atazanavir, vincristine, midazolam, vardenafil, otenabant, verapamil, and tacrolimus, whereas 17 of the 32 tested showed negligible CYP3A5 contribution. For specific reactions in HLMs from *1/*1 donors, CYP3A5 contributes 55% and 44% to midazolam 1′- and 4-hydroxylation, 16% to testosterone 6β-hydroxylation, 56% and 19% to alprazolam 1′- and 4-hydroxylation, 10% to tamoxifen N-demethylation, and 58% to atazanavir p-hydroxylation. Comparison of the in vitro observations to clinical pharmacokinetic data showed only a weak relationship between estimated contribution by CYP3A5 and impact of CYP3A5 genotype on oral clearance, in large part because of the scatter in clinical data and the low numbers of study subjects used in CYP3A5 pharmacogenetics studies. These data should be useful in guiding which drugs should be evaluated for differences in pharmacokinetics and metabolism between subjects expressing CYP3A5 and those who do not express this enzyme.Keywords
This publication has 59 references indexed in Scilit:
- Impact of CYP3A5 Genotype on Tacrolimus Versus Midazolam Clearance in Renal Transplant Recipients: New Insights in CYP3A5-Mediated Drug MetabolismPharmacogenomics, 2013
- In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant PatientsClinical Pharmacology & Therapeutics, 2012
- A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant RecipientsTherapeutic Drug Monitoring, 2010
- Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2010
- Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressorsJournal of Antimicrobial Chemotherapy, 2009
- Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With TacrolimusTransplantation Proceedings, 2009
- Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B5Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2008
- Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5Drug Metabolism and Disposition, 2006
- The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA PerspectiveThe Journal of Clinical Pharmacology, 2003